TCF7L2 and hepatocellular carcinoma: To determine whether TCF7L2 regulates migration and invasion via AKT/mTOR pathway in HCC, SK1 and Huh7 cells overexpressing TCF7L2 were treated with the AKT inhibitor MK-2206 and the mTOR inhibitor Rapamycin.